

Special Issue

Anti-microbial Activity of Metabolites Isolated from Fungi

Message from the Guest Editors

Fungi are a noteworthy source of bioactive metabolites, but differently from plants, their metabolite contents have been much less investigated to this purpose. Several new molecules have been discovered in the past few years, but what is still missing is a systematic study of the active molecules synthesized by many taxonomic units. For instance, some genera belonging to phylum Basidiomycota, such as *Cortinarius*, *Entoloma*, *Russula*, *Mycena*, and *Inocybe*, have been only minimally investigated. The inhibition of bacterial growth is a prominent property of several fungal compounds. Since the discovery of penicillin, more than 150 different antibiotics have been isolated and used for human therapy. However, bacteria developed resistance against most of these molecules, so that antimicrobial resistance is now one of the most concerning global threats for human health. This Special Issue will address studies that focus on fungal metabolites from both mycelial broth culture and fruiting bodies, with a specific potential application for their antibiotic activity against bacterial and fungal human pathogens.

Guest Editors

Dr. Marco Clericuzio

Dr. Elisa Gamalero

Dr. Elisa Bona

Deadline for manuscript submissions

closed (20 October 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/70916

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)